Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care:... IntroductionPsoriasis is a chronic inflammatory, immune‐mediated skin disease affecting 1–3% of the industrialized population. There are several treatment options available for moderate to severe psoriasis that can provide improvements in clinical assessments of skin symptoms [e.g. Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI)]. The disease is associated with both physical and psychological impairments, and hence, optimal control requires adherence to continuous treatment.PROSPECT (Observational, Descriptive Study of Prior and Concomitant Psoriasis Treatments in Subjects Receiving Secukinumab in the Routine Treatment of Moderate to Severe Plaque‐type Psoriasis; EUPAS10715) is a descriptive study designed to assess prior and concomitant use of psoriasis treatments in subjects receiving secukinumab, and the duration of transition periods from prior treatments to secukinumab treatment in Germany. Previous studies report the prevalence of psoriasis for individuals of all ages in Germany as 2.00% (95% confidence internal (CI): 1.98–2.20) and 2.53% (95% CI: 2.50–2.56). German and European treatment guidelines for psoriasis recommend combinations of various psoriasis treatments for selected subjects and purposes. For example, topical treatments are often combined with both conventional systemic treatments and biologics, and conventional systemic treatments are sometimes combined with biologics. A recent international consensus report http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study

Loading next page...
 
/lp/wiley/secukinumab-treatment-of-moderate-to-severe-plaque-psoriasis-in-ii9eKZcebJ
Publisher
Wiley
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14604
Publisher site
See Article on Publisher Site

Abstract

IntroductionPsoriasis is a chronic inflammatory, immune‐mediated skin disease affecting 1–3% of the industrialized population. There are several treatment options available for moderate to severe psoriasis that can provide improvements in clinical assessments of skin symptoms [e.g. Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI)]. The disease is associated with both physical and psychological impairments, and hence, optimal control requires adherence to continuous treatment.PROSPECT (Observational, Descriptive Study of Prior and Concomitant Psoriasis Treatments in Subjects Receiving Secukinumab in the Routine Treatment of Moderate to Severe Plaque‐type Psoriasis; EUPAS10715) is a descriptive study designed to assess prior and concomitant use of psoriasis treatments in subjects receiving secukinumab, and the duration of transition periods from prior treatments to secukinumab treatment in Germany. Previous studies report the prevalence of psoriasis for individuals of all ages in Germany as 2.00% (95% confidence internal (CI): 1.98–2.20) and 2.53% (95% CI: 2.50–2.56). German and European treatment guidelines for psoriasis recommend combinations of various psoriasis treatments for selected subjects and purposes. For example, topical treatments are often combined with both conventional systemic treatments and biologics, and conventional systemic treatments are sometimes combined with biologics. A recent international consensus report

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off